CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.
about
Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virusMultiple functions of microsomal triglyceride transfer proteinJTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs.Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteinsSecretion of Hepatitis C Virus Envelope Glycoproteins Depends on Assembly of Apolipoprotein B Positive LipoproteinsTargeting host factors: A novel rationale for the management of hepatitis C virusApolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus ParticlesDirlotapide, a U.S. Food and Drug Administration-approved first-in-class obesity drug for dogs-will humans be next?Sterol regulatory element binding protein 1a regulates hepatic fatty acid partitioning by activating acetyl coenzyme A carboxylase 2Microsomal Triglyceride Transfer Protein (MTP) Associates with Cytosolic Lipid Droplets in 3T3-L1 AdipocytesPostprandial changes in high density lipoproteins in rats subjected to gavage administration of virgin olive oilReduced heart size and increased myocardial fuel substrate oxidation in ACC2 mutant micePharmacologic inhibition of phospholipid transfer protein activity reduces apolipoprotein-B secretion from hepatocytes.Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.Identification and characterization of dual inhibitors for phospholipid transfer protein and microsomal triglyceride transfer protein.ApoO, a novel apolipoprotein, is an original glycoprotein up-regulated by diabetes in human heart.Emerging drugs for hyperlipidemia.Microsomal triglyceride transfer protein enhances cellular cholesteryl esterification by relieving product inhibition.Acute suppression of apo B secretion by insulin occurs independently of MTP.The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical speciesLiver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasisChronic activation of FXR in transgenic mice caused perinatal toxicity and sensitized mice to cholesterol toxicity.ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5)New treatments for chronic hepatitis C.Acetyl-CoA carboxylase 2-/- mutant mice are protected against fatty liver under high-fat, high-carbohydrate dietary and de novo lipogenic conditions.Camphene, a Plant Derived Monoterpene, Exerts Its Hypolipidemic Action by Affecting SREBP-1 and MTP ExpressionQuantifying apoprotein synthesis in rodents: coupling LC-MS/MS analyses with the administration of labeled water.Antisense oligonucleotides as therapeutics for hyperlipidaemias.Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia.MTP inhibition as a treatment for dyslipidaemias: time to deliver or empty promises?Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.Microsomal triglyceride transfer protein inhibition induces endoplasmic reticulum stress and increases gene transcription via Ire1α/cJun to enhance plasma ALT/ASTAcquisition of triacylglycerol transfer activity by microsomal triglyceride transfer protein during evolution.New approaches to target microsomal triglyceride transfer protein.Apolipoprotein B100 biogenesis: a complex array of intracellular mechanisms regulating folding, stability, and lipoprotein assembly.Advancing therapy for hypercholesterolemia.Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis.Emerging options in the treatment of dyslipidemias: a bright future?Cholesterol and chronic hepatitis C virus infection.Diagnosis and treatment of severe hypertriglyceridemia.
P2860
Q21090530-F0F25C91-8AB6-4103-808D-C2A77BB801E4Q21245057-B9492A2D-BF37-428C-B6E6-0054FE793D4BQ24814905-338E52E3-8D94-4CA8-8C88-BCC064547473Q27478188-6D7C24AB-2BE8-4E84-9133-FE79EA9F1939Q27487558-FCA47570-0D79-4C57-BA4A-27A1B871D0AEQ27488999-90A32D9C-09E5-46E5-B34A-42C87C19379DQ27490474-92738D42-1076-47EE-A4F0-762AB359A776Q28263435-6E7D0E4B-3AB9-4763-8AF2-6E1A6ED877B0Q28511448-5EF9A2A3-7039-4011-BFB8-E91D3A837D97Q28547210-AF670254-F7D3-4941-96A6-4092FF03584FQ28569962-3E6924B1-151C-4593-A026-C15E22821CA1Q28584714-4C72BFCC-ACA2-4759-993D-68BC6575A95EQ33714941-79E508A6-4B96-4E4F-998D-239470F8C329Q33784492-043EAD91-D874-4469-BA83-9464922CBDA0Q34359986-8622C677-1777-48C4-8B26-EC29F98C504FQ34563979-B169913D-1693-490B-88D4-A3595980A376Q34619115-2132650E-CA22-48E0-9EF9-2151257028A2Q34656363-F26DFD73-DF31-4102-930C-D476D6ADF929Q34669545-70FF06E7-E615-4395-807D-57608113A635Q34955865-FDAF045B-806C-4588-B155-5B780A517DBEQ35039363-C04CFDF5-ACB9-4B17-9670-4633ADA0650EQ35441714-1A55AF6E-6893-4F19-B84B-77CEF5B27464Q35541914-13F8FB0D-CDD4-4CFE-B4D1-00776934FEA1Q35833006-A94538C5-AD4C-42D6-A145-250870F36E3BQ35874567-098A15FB-BEC4-4ED7-AC15-F1523D9AEA55Q35897695-8A8BF7C3-3DED-4780-BE60-0F0774A3C934Q35958503-3FD70C0F-B362-4C6D-B313-E800D5EB902BQ36194069-FD48E876-1666-4D88-8ECC-27318E2214F1Q36623056-B5C3872A-A410-4A25-A990-E5238546D692Q36709542-773BC0F6-F102-4132-A981-CB05E3C8095AQ36770743-67BB0EF5-627A-4937-ACAD-7DCF1D20C0DDQ36850321-DF42643D-C834-4DC5-B974-98E9ABB0C3BBQ36876603-82194AE2-A313-4AFC-A5E3-2976A3F129BCQ37114977-9861176A-DE72-49E8-918A-406ABEB2FB80Q37746984-13732596-A981-4E7A-A801-FCFC5768E405Q37761373-2BCC4139-1F90-410B-B38C-B8C22F866728Q37788976-BD1F6257-A4AF-4857-8071-880F33D33296Q37842462-85BC5E78-73FD-4479-BFEF-0512B379A159Q37891171-9169DC60-1030-49EF-94BA-A5D13E011205Q37998115-A0AAF4BE-F3D7-40A4-80A5-2CB687615F88
P2860
CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@en
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@nl
type
label
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@en
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@nl
prefLabel
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@en
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@nl
P2093
P2860
P1476
CP-346086: an MTP inhibitor th ...... imental animals and in humans.
@en
P2093
Charles E Chandler
Donald E Wilder
George Chang
H James Harwood
John Vincent
Judith L Pettini
Stephen F Petras
Yvette E Savoy
P2860
P304
P356
10.1194/JLR.M300094-JLR200
P577
2003-07-01T00:00:00Z